Passage Bio, Inc. (NASDAQ:PASG - Get Free Report) major shareholder Lynx1 Capital Management Lp purchased 29,300 shares of Passage Bio stock in a transaction dated Wednesday, November 27th. The shares were bought at an average cost of $0.67 per share, for a total transaction of $19,631.00. Following the transaction, the insider now directly owns 8,883,308 shares of the company's stock, valued at approximately $5,951,816.36. The trade was a 0.33 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Lynx1 Capital Management Lp also recently made the following trade(s):
- On Monday, November 25th, Lynx1 Capital Management Lp acquired 259,998 shares of Passage Bio stock. The shares were purchased at an average price of $0.56 per share, for a total transaction of $145,598.88.
Passage Bio Trading Down 11.2 %
Shares of Passage Bio stock opened at $0.67 on Thursday. The stock has a market capitalization of $41.17 million, a price-to-earnings ratio of -0.57 and a beta of 1.20. Passage Bio, Inc. has a twelve month low of $0.45 and a twelve month high of $1.79. The business's 50 day simple moving average is $0.61 and its 200-day simple moving average is $0.82.
Analyst Upgrades and Downgrades
WARNING: “Buffett Indicator” flashing for first time in 50 years
From Behind the Markets | Ad
Warren Buffett has sold a staggering $97 billion worth of stocks this year...
But why?
Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash.
His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.
Take these 4 steps today to protect your retirement NOW
PASG has been the subject of several research reports. Chardan Capital reiterated a "buy" rating and issued a $7.00 target price on shares of Passage Bio in a research report on Thursday, November 14th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $13.00 price objective on shares of Passage Bio in a report on Thursday, November 14th. Finally, Rodman & Renshaw began coverage on shares of Passage Bio in a research report on Tuesday, September 3rd. They issued a "buy" rating and a $7.00 price target on the stock.
Read Our Latest Report on PASG
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in PASG. Lynx1 Capital Management LP lifted its stake in Passage Bio by 1,178.1% in the first quarter. Lynx1 Capital Management LP now owns 4,845,871 shares of the company's stock valued at $6,542,000 after buying an additional 4,466,712 shares during the last quarter. Erste Asset Management GmbH bought a new position in shares of Passage Bio during the third quarter worth about $1,718,000. Geode Capital Management LLC increased its holdings in shares of Passage Bio by 18.2% in the 3rd quarter. Geode Capital Management LLC now owns 509,516 shares of the company's stock worth $357,000 after acquiring an additional 78,406 shares during the period. Landscape Capital Management L.L.C. bought a new stake in Passage Bio in the 3rd quarter valued at about $38,000. Finally, Vanguard Group Inc. lifted its position in Passage Bio by 2.6% in the 1st quarter. Vanguard Group Inc. now owns 2,071,538 shares of the company's stock valued at $2,797,000 after purchasing an additional 52,656 shares during the last quarter. 53.48% of the stock is currently owned by institutional investors.
About Passage Bio
(
Get Free Report)
Passage Bio, Inc, a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
